Shanghai Hengrui Pharmaceutical Co., Ltd.
PharmaShanghai, China, China · Est. 1995
Shanghai Hengrui Pharmaceutical is a Chinese pharmaceutical company focused on developing innovative drugs in oncology, cardiovascular disease, and other therapeutic areas.
15
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
20
Indications↗
Distinct diseases across all programs
64
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
15 drugs in development
Phase 31
Phase 213
Phase 14
Preclinical1
By Therapeutic Area
top 2
Oncology
1376%
Neurology
16%
R&D Momentum
60/100
Pipeline Velocity
27/100
Trial Completion Rate
86/100
Pipeline Concentration
62/100
Pipeline Freshness
75/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Neurology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 18, 2026
Recruiting
A Phase I/II, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7787 in Patients With Advanced Solid Tumors
Sep 11, 2026
Completed
A Phase 1 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food on the Bioavailability of HRS-6257 in Healthy Subjects
Earlier
Sep 3, 2026TrialA Multicenter, Open-label, Phase Ⅱ Clinical Study of SHR-7787 Injection Combined With Adebrelimab in Patients With Limited Stage Small Cell Lung Cancer
Aug 25, 2026TrialA Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors
Aug 22, 2026TrialA RANDOMIZED, DOUBLE-BLIND, DOSE-ESCALATION, PLACEBO-CONTROLLED PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Jul 17, 2026TrialA Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of SHR-7367 in Subjects With Advanced Solid Tumors
Apr 1, 2026TrialA Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Jan 8, 2026TrialHRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
4 more events
Dec 23, 2025TrialA Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Dec 2, 2025TrialA Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Nov 24, 2025TrialA Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Jul 24, 2025TrialPhase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
OncologyCardiovascularAnti-infectives
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neurology(1 drug)
—
—
1
—
—
Neurology(1 drug)
Oncology(13 drugs)
1
4
11
1
—
Oncology(13 drugs)
Unknown / Other(3 drugs)
—
1
2
—
—
Unknown / Other(3 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)